No Data
No Data
Viridian Therapeutics CEO Buys $499.3K in Common Stock
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
BTIG Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $61
Viridian Therapeutics Price Target Raised to $61 From $56 at BTIG
Buy Rating for Viridian Therapeutics: Leading the TED Market With Innovative SC Treatment VRDN-003
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
No Data
No Data